Ivermectina en agentes de salud e IVERCOR COVID19

IVERCOR PREP, Preliminary Results, Dec 2020
ProphylaxisRetrospective · 875 patients · Argentina
Ivermectin for COVID-19
IVERCOR PREP Preliminary Results · December 2020
Outcome
Improvement
← favors ivermectinfavors control →
Case
73%0.27 · 0.15–0.48
00.511.52+
Risk ratio · 95% CI · 1 = no difference
Fewer cases with ivermectin
p < 0.000001
Does ivermectin reduce COVID-19 infections?
c19early.org
ProphylaxisRetrospective · 875 patients · Argentina
Ivermectin for COVID-19
IVERCOR PREP Preliminary Results · December 2020
Improvement
← favors ivermectinfavors control →
Case
73%0.27 · 0.15–0.48
00.511.52+
Fewer cases with ivermectin
p < 0.000001
Does ivermectin reduce COVID-19 infections?
c19early.org
ProphylaxisRetrospective · 875 patients · Argentina
Ivermectin for COVID-19
IVERCOR PREP Preliminary Results · December 2020
Improvement
← favors ivermectinfavors control →
Case
73%0.27 · 0.15–0.48
00.511.52+
Fewer cases with ivermectin
p < 0.000001
Does ivermectin reduce COVID-19 infections?
c19early.org
Case 73% improvement lower risk ← → higher risk Ivermectin for COVID-19  IVERCOR PREP  PROPHYLAXIS Does ivermectin reduce COVID-19 infections? Retrospective 875 patients in Argentina Fewer cases with ivermectin (p<0.000001) c19early.org IVERCOR PREP, Preliminary Results, Dec 2020 0 0.5 1 1.5 2+ RR
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.0000000001 from 106 studies, recognized in 24 countries.
Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,700+ studies for 220+ treatments. c19early.org
Meta-analysis
Report on ivermectin prophylaxis in a hospital in Argentina showing lower cases for healthcare workers taking ivermectin.
Results have been published in the press1 (interim results), and a presentation posted online:2, however there is no formal publication to date.
These results would be expected to receive priority publication due to the predicted impact on the pandemic and confirmation of previous prophylaxis studies. The lack of formal publication suggests a negative publication bias that may be due to politicization in the authors' location.
Note that this prophylaxis study is different to the Vallejos early treatment trial.
This is the 28th of 106 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001.
54 studies are RCTs, which show efficacy with p=0.000000027.
This study is excluded in the after exclusion results of meta-analysis: minimal details provided.
Important missing comments or errors? Let us know.
risk of case, 73.4% lower, RR 0.27, p < 0.001, treatment 13 of 389 (3.3%), control 61 of 486 (12.6%), NNT 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
IVERCOR PREP et al., 20 Dec 2020, retrospective, Argentina, preprint, 1 author, dosage 12mg weekly.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org September 2026 Argentina Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Vietnam Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Argentina favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org September 2026 Argentina Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Spain Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Argentina favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0